Liver and intrahepatic bile duct neoplasm

This early-phase study tests a personalized mRNA cancer vaccine (XH001) given alongside standard treatment after surgery for people with high-risk solid tumors (bile duct, gallbladder, pancreatic, liver, or stomach cancer). The main goals are to check safety and see if the vaccin…

This early-stage trial is testing a new drug called ADCE-B05 in 180 people with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to …

This study tests a new drug called ALE.P03 in adults with advanced or metastatic solid tumors that have a specific protein (Claudin-1) on their surface. The drug is an antibody-drug conjugate designed to deliver a toxic payload directly to cancer cells. The trial has two phases: …

This trial investigates whether adding a Braun anastomosis—a connection between two loops of the small intestine—during pancreatic cancer surgery can lower the risk of delayed gastric emptying, a frequent complication where the stomach takes too long to empty. About 264 adults sc…

This early-phase study tests an experimental drug called DM002 in about 160 people with advanced solid tumors (ovarian, prostate, endometrial, colorectal, or other solid cancers). The study has two parts: first, finding a safe dose by giving small groups gradually higher doses; s…

This phase 1 trial tests a new drug called AWT020, given alone or with other cancer treatments, in people with advanced solid tumors such as non-small cell lung cancer, colorectal cancer, kidney cancer, and melanoma. The main goals are to check the drug's safety, find the best do…

This early-stage study tests a new drug called casdatifan (AB521) alone or combined with other cancer drugs in people with advanced clear cell kidney cancer or other solid tumors. The main goals are to check safety and find the right dose. About 362 participants will take part.

This study tests a new way to treat advanced liver cancer that has spread. It combines an immunotherapy drug (adebrelimab) with a blood vessel blocker (bevacizumab) and standard chemotherapy, all given directly into the liver's main artery or through a vein. The goal is to see if…

This study tests a new drug called ASP546C in people with advanced stomach, gastroesophageal junction, pancreatic, or certain other solid tumors. The drug is given as an infusion every 3 weeks. The study has two parts: Part 1 finds the best dose in stomach/GEJ cancer patients, an…

This early-phase trial is testing a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in people with solid tumors. The vaccine is custom-made for each patient to target their specific cancer. The study aims to check the safety of this combina…

This early-phase trial tests a new drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatment or have no effective therapy. The drug is taken by mouth in 21-day cycles and aims to reactivate genes that may slow tumor growth. The main goal…

This early-stage trial is testing an experimental drug called BMS-986500 in people with advanced solid tumors or breast cancer that has not responded to prior treatments. The study will first test the drug alone, then in combination with other cancer drugs (palbociclib and fulves…

This trial tests whether giving the immunotherapy drug durvalumab along with standard chemotherapy before surgery can shrink high-risk liver cancer (cholangiocarcinoma) and reduce the amount of tissue that needs to be removed. About 27 patients with resectable tumors will receive…

This study tests whether adding a targeted, tumor-destroying treatment (like focused radiation or heat ablation) can help people with certain gastrointestinal cancers—such as colorectal, small bowel, or pancreatic cancer—continue their current systemic therapy longer when only a …

This study tests a new drug called IMA402 in people with advanced solid tumors that have come back or not responded to treatment. IMA402 is designed to help the immune system attack cancer cells. The trial will check if the drug is safe and whether it can shrink tumors.

This early-stage trial tests a new type of immunotherapy where a patient's own T cells are genetically engineered to recognize and attack cancer cells with a specific KRAS G12D mutation. The study includes adults with advanced lung, colorectal, pancreatic, or endometrial cancers …

This study tests a new drug called IPN01203 in about 102 adults with advanced solid tumors that have spread and stopped responding to immunotherapy. The trial has two parts: first, finding a safe dose, then testing low versus high doses to see if the drug can shrink tumors. Parti…

This early-stage trial tests a daily oral drug called CGT6297 in 90 adults with advanced solid tumors that have a specific mutation in the PIK3CA gene. The study has two parts: first, finding a safe dose, and then looking for signs that the drug shrinks tumors. It focuses on peop…

This phase II trial tests whether a combination of durvalumab (an immunotherapy), chemotherapy (GEMOX or GC), followed by lenvatinib (a targeted therapy) can prevent biliary tract cancer from coming back after surgery. About 222 adults with bile duct or gallbladder cancer will be…

This study is testing a new biologic drug called sacituzumab tirumotecan (MK-2870), alone or with chemotherapy, in people with advanced colorectal, pancreatic, or biliary tract cancers that cannot be removed by surgery. The main goals are to check safety and see if tumors shrink.…

This study tests a new drug called IPN01195 in about 85 adults with advanced solid tumors that have spread and no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have certain genetic changes in their …

This phase 2 trial is testing a combination of three drugs (cabozantinib, ipilimumab, and nivolumab) plus a procedure called TACE in 35 people with liver cancer that cannot be cured by surgery or transplant. The goal is to see if this approach can stop the cancer from growing for…

This phase 3 trial tests a new drug called nanvuranlat in 480 adults with advanced biliary tract cancer that has worsened after prior treatment. Participants receive either nanvuranlat or one of several standard treatments. The main goal is to see if nanvuranlat helps people live…

This study observes how a combination of two immunotherapy drugs, nivolumab and ipilimumab, works for people with advanced liver cancer that cannot be removed by surgery. It follows adults receiving this treatment as part of their routine medical care in Japan to understand its s…

The DETERMINE trial is testing whether drugs already approved for some cancers can help people with rare cancers or common cancers that have rare genetic mutations. It will enroll 825 adults, teenagers, and children whose cancers have specific DNA changes. The goal is to find new…

This study tests whether placing a small tube (stent) in the pancreas during Whipple surgery can prevent a common complication called pancreatic fistula, where digestive fluid leaks out. The trial will compare 100 patients with a soft pancreas who either get the stent or not. The…

This early-phase study tests a new drug called PYX-201 in people with advanced solid tumors that have come back or spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 330 adults with certain breast, head and neck, or other cancers are being…

This early-stage study tests a new oral drug, DEG6498, in about 100 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and understand side effects. Participants take the drug once daily and are closely monitore…

This study tests a drug called tivozanib in people with bile duct cancer that cannot be removed by surgery and has already been treated with chemotherapy. The goal is to find the safest dose and see if the drug can shrink tumors or slow the cancer. Participants take tivozanib by …

This early-stage trial tests a new drug, BAY 3547926, that delivers radiation directly to liver cancer cells with a specific protein (GPC3). The goal is to find a safe dose and see if it shrinks tumors. About 148 adults with advanced liver cancer will take part in four groups, so…

This early-stage trial tests an experimental drug called E303 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goals are to check safety and see if the …

This study is for people with advanced liver cancer (hepatocellular carcinoma) who also have moderate cirrhosis (Child-Pugh B7 or B8). It tests the safety of two drugs, atezolizumab and bevacizumab, given together or alone as a first treatment. The goal is to see if these drugs a…

This study provides ongoing treatment with the cancer drug adagrasib (BMS-986503) to patients with advanced solid tumors who have already seen benefit in earlier studies. About 170 adults with non-small cell lung cancer, colorectal cancer, or other solid tumors can join if they a…

This early-phase study tests a new drug called XMT-1660 in about 319 people with advanced solid tumors, including breast, ovarian, and endometrial cancers. The main goals are to find the safest dose and check for side effects. Researchers will also see if the drug shrinks tumors.…

This early-stage trial is testing an investigational drug called CX-801, alone or with the immunotherapy Keytruda, in 121 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will…

This study tests a new drug called STK-012, which is designed to boost the immune system's ability to fight cancer. It is being tested alone or with standard treatments (pembrolizumab, pemetrexed, carboplatin) in people with advanced solid tumors, especially those with a type of …

This study tests a new drug called HRS-4508 in combination with other cancer treatments (such as capecitabine, trastuzumab, and pertuzumab) for people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find the best dose, check safety, and…

This early-phase trial tests a new oral drug called IPG7236 combined with the immunotherapy toripalimab in adults with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding the safest dose of IPG7236, then expanding to see if the com…

This early-stage study tests a new drug called MK-4884 in about 120 people with advanced or metastatic solid tumors (colorectal, kidney, lung, or bile duct cancer). The main goal is to check the drug's safety and find the right dose. Researchers will monitor side effects and how …

This study is testing a drug called patritumab deruxtecan in people with advanced gastrointestinal cancers that have spread. The drug is given through a vein and aims to shrink tumors. The trial will check how safe the drug is and how many people's cancers respond to treatment. A…

This early-phase trial is testing an experimental oral drug called KST-6051 in adults with advanced or metastatic solid tumors that have a KRAS mutation, including certain lung, pancreatic, and colorectal cancers. The main goal is to check the drug's safety and how the body proce…

This early-stage trial tests a new drug called YL211 in 155 people with advanced solid tumors who have no standard treatment options left. The study has three parts: first, finding a safe dose; then, confirming that dose; and finally, testing how well it works. The main goals are…

This study tests a new drug called CR-001 in adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if it can shrink tumors. About 290 people will take part in this early-phase trial.

This study is testing the drug T-DXd (Enhertu) in 100 adults with advanced HER2-positive solid tumors who have already tried other treatments and have no good options left. The goal is to see how well the drug works in real-world settings, including how many patients respond and …

This study tests a new drug called pumitamig, alone or with another drug (ipilimumab), in people with advanced liver cancer that cannot be removed by surgery. The trial includes 198 participants who have not had prior cancer treatment. The goal is to see if the drugs are safe and…

This early-stage trial tests a new oral drug called ERAS-0015, alone or with other cancer drugs, in 600 adults with advanced solid tumors that have certain RAS mutations. The main goals are to check safety, find the right dose, and see how the drug moves through the body. Researc…

This phase II trial is testing a combination of three drugs—trastuzumab rezetecan, adebrelimab, and lenvatinib—as a first treatment for people with advanced or metastatic biliary tract cancer that has HER2 markers. The study aims to see how well the drugs shrink tumors and contro…

This study is checking the long-term safety and effectiveness of the cancer drug pembrolizumab (Keytruda) in 3500 people with various solid tumors or blood cancers. Participants are moving from earlier Merck studies into this one, continuing their treatment or follow-up. The goal…

This Phase 2 trial is testing two doses (20 mg and 16 mg) of the oral drug futibatinib in 120 people with advanced bile duct cancer that has specific FGFR2 gene changes. Participants must have already tried standard chemotherapy. The study aims to see which dose works better at s…

This Phase 2 trial is testing a combination of three drugs—gemcitabine, mitomycin C, and thalidomide—given in low, frequent doses to people with advanced solid tumors that have not responded to prior treatments. The goal is to see if this approach can slow tumor growth and improv…

This early-stage trial tests an experimental oral drug called NKT5097 in adults with advanced solid tumors, especially breast cancer. The drug works by breaking down two proteins that help cancer cells grow. Researchers want to find the safest dose and see if it can shrink tumors…

This early-stage trial tests a new oral drug called SNV1521 in 400 people with advanced solid tumors that have spread. The main goals are to check safety, find the best dose, and see if it can shrink tumors. Researchers will also test SNV1521 combined with other cancer drugs.

This study tests a new drug called XTX301 in people with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and then testing that dose in specific cancer types. Researchers will monitor side effects and wheth…

This phase 2 trial is testing whether adding common diabetes drugs (metformin or rosiglitazone) to standard immunotherapy (nivolumab or pembrolizumab) can improve treatment for several advanced solid tumors, including melanoma, lung cancer, and liver cancer. About 72 participants…

This phase 2b trial tests whether adding visugromab and nivolumab to standard lenvatinib can help people with advanced liver cancer that has worsened after initial treatment. About 104 participants will receive either the triple combination or a placebo plus lenvatinib. The study…

This early-phase trial tests a new drug called BI-1206, given alongside the immunotherapy pembrolizumab, in adults with advanced solid tumors that have stopped responding to prior anti-PD-1/PD-L1 treatment. The study aims to find the safest dose and check for early signs of tumor…

This early-phase trial is testing a new drug called PHST001, which helps the immune system attack cancer cells by blocking a protein called CD24. The study will first test PHST001 alone, then in combination with standard chemotherapy, in adults with advanced solid tumors (includi…

This early-stage trial tests a new drug called ONC-841 in people with advanced solid tumors that have spread. The drug is an antibody designed to help the immune system attack cancer cells. The study will first find a safe dose, then test it alone and with standard treatments for…

This first-in-human study tests an experimental drug called CX-2051, alone or with Avastin, in 160 adults with advanced solid tumors that have worsened after standard treatment. The main goals are to check safety and find the right dose, while also looking for early signs of tumo…

This study tests an experimental oral drug called NTS071 in adults with advanced solid tumors that have a specific change in the TP53 gene (Y220C mutation). The trial has two parts: first, finding a safe dose, and then checking if the drug can shrink tumors. About 220 people who …

This early-phase trial tests a new drug called BI 3810944 in adults with advanced solid tumours or melanoma who have no other treatment options. The study aims to find a safe and tolerable dose, and to see if the drug can shrink tumours. Participants receive the drug every three …

This study tests a drug called zanzalintinib in people with advanced liver cancer that has spread or cannot be cured. The trial has two parts: first, finding the safest dose, then checking if it helps control the cancer. About 59 participants will take the drug by mouth, and rese…

This extension study follows people with von Hippel-Lindau (VHL) disease or advanced solid tumors who are already taking belzutifan in another trial. The goal is to see how long they live and how safe the drug is over the long term. About 450 participants will take belzutifan by …

This study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…

This study provides continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to track long-term side effects and safety over ti…

This early-stage trial is testing a new biologic drug called XB628, alone or with an oral drug called zanzalintinib, in people with advanced or metastatic solid tumors that have not responded to prior treatments. The study has two parts: first, finding a safe dose, and then check…

This study tests a new combination of an immunotherapy drug (adebrelimab) plus two chemotherapy drugs (gemcitabine and nab-paclitaxel) as a first treatment for people with biliary tract cancer that cannot be removed by surgery. The goal is to see if this combo can shrink tumors a…

This early-stage study is testing a new treatment called SynKIR-110 for people with advanced ovarian cancer, bile duct cancer, or mesothelioma that has spread or come back. The treatment involves taking a patient's own immune cells, engineering them in a lab to better recognize a…

This trial tests a new type of immune cell therapy called bi-specific CAR-T cells that target two proteins (GD2 and PSMA) found on some solid tumors. The study involves 60 patients whose tumors have not responded to standard treatments. Researchers will check safety and whether t…

This study looks at whether removing the entire pancreas is better than removing just part of it for people with certain cancers in the head of the pancreas who are at high risk of complications. The main goal is to see if total removal helps patients live longer without hurting …

This study is tracking 100 adults with a rare and aggressive bile duct cancer that has a specific IDH1 gene mutation. Participants will take the targeted drug ivosidenib, which was recently approved in Europe. Researchers will monitor how long the cancer stays under control, over…

This study tests an experimental mRNA therapy called mRNA-4359, given alone or with standard immunotherapy drugs, in people with advanced solid tumors (like melanoma, lung cancer, or colorectal cancer). The main goals are to find a safe dose and see if the treatment can shrink tu…

This early-stage trial is testing a new drug called lunresertib, alone or combined with two other experimental drugs (RP-3500 and Debio 0123), in people with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for earl…

This study is testing a drug called patritumab deruxtecan in children whose liver or muscle cancers have returned or not responded to treatment. The drug works like a smart bomb, attaching to a protein on cancer cells to deliver a toxic payload. The trial will check if it is safe…

This study tests OTP-01, a new drug that targets two cancer pathways (PD-1 and VEGFR2) at once, in 170 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the best dose, check safety, and see if the drug can shrink tum…

This study tests a drug called eflapegrastim in 40 children with solid tumors or lymphoma who are receiving chemotherapy. The drug aims to boost white blood cells and reduce the risk of serious infections. Researchers are checking how safe it is and how the body processes it.

This early-stage trial is testing a new drug called IDE892, alone or with another drug (IDE397), in people with advanced solid tumors that have a specific genetic deletion (MTAP). The study aims to find safe doses and see if the drugs shrink tumors. It includes 260 adults with ca…

This study is testing whether giving chemotherapy (capecitabine or S-1) together with radiation after surgery can help prevent bile duct and gallbladder cancers from coming back. It includes 92 patients whose cancers had high-risk features, like positive lymph nodes or narrow sur…

This early-stage trial tests an experimental drug called mocertatug rezetecan in 675 adults with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a toxin directly to cancer cells. The main goals are to check safety, find the ri…

This study tests a new treatment called 4SCAR-276 for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells that have a protein called CD276. The tria…

This study tests whether adding the anti-inflammatory drug celecoxib to standard immunotherapy and chemotherapy can help people with advanced bile duct cancer live longer without their disease getting worse. The trial focuses on patients whose tumors have high levels of a marker …

This early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …

This study tests a new daily pill, ETX-636, for people with advanced solid tumors (including breast cancer) that have a specific genetic change called PIK3CA. The trial has two parts: first, finding a safe dose of ETX-636 alone or with another drug (fulvestrant); second, checking…

This study is testing a treatment called BSJ019T in Japanese patients with liver cancer that cannot be removed by surgery and has not responded to standard treatments. The goal is to see if the treatment can control the cancer's growth and how safe it is. About 51 participants wi…

This early-stage trial tests an experimental drug called SAR445877, alone or with other cancer drugs, in adults with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding a safe dose, and second, checking if the drug shrinks tumors. …

This study tests whether removing as much tumor as possible through surgery before giving a targeted radioactive drug (Lutetium Lu 177 dotatate) works better for people with slow-growing neuroendocrine tumors that have spread to the liver. Six adults with grade 1 or 2 tumors will…

This phase 3 trial is for people with advanced liver cancer that has spread to nearby blood vessels. It compares standard immunotherapy drugs (atezolizumab and bevacizumab) alone versus the same drugs plus targeted radiation (SBRT). The goal is to see if adding radiation helps pa…

This early-phase study tests a new drug, BG-C477, in about 310 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is open-label, meaning ev…

This early-stage trial is testing a new drug called BGB-58067, alone or with other cancer treatments, in people with advanced solid tumors that have a specific genetic change (MTAP deficiency). The study aims to find the safest dose and see if the drug can shrink tumors. About 52…

This trial tests a new drug called N17350, a modified enzyme injected directly into tumors, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find the safest and most effective dose, and to see if the drug can shrink or stop tu…

This phase 2 trial is testing a drug called calderasib (MK-1084), given alone or with cetuximab, in 150 people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the cancer shrinks or disappears and to check for side effects. Participants mu…

This phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study …

This study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…

This study tests an experimental drug called Tulmimetostat (DZR123) in people with advanced solid tumors or lymphomas that have not improved with standard treatments. The drug is taken as a daily pill, either alone or combined with another drug (enzalutamide) for certain prostate…

This study tests a new drug called SW-682, taken as a tablet, for people with advanced solid tumors that have not responded to standard treatments. The trial focuses on tumors with changes in the Hippo pathway, including mesothelioma. In the first part, doctors will find the safe…

This phase 2 trial tests whether a series of procedures to remove cancerous tumors, given one after another, can improve outcomes for people with stage IV foregut cancers (like stomach, pancreas, or bile duct cancer) who have no detectable cancer DNA in their blood after initial …

This clinical trial is testing several combinations of immunotherapy drugs to see if they can shrink or control advanced liver cancer. The study is for people with a type of liver cancer called hepatocellular carcinoma (HCC) that has spread or cannot be removed by surgery. Partic…

This early-stage study tests a new drug called ZL-6201 in adults with sarcoma or certain solid tumors that have spread or cannot be removed by surgery. The main goal is to check the drug's safety and find the right dose. About 180 people will take part in this study.

This phase 1 trial tests an experimental drug, DXC006, in people with advanced solid tumors (like small cell lung cancer and neuroblastoma) or blood cancers (like multiple myeloma) who have not responded to standard treatments. DXC006 is an antibody-drug conjugate designed to del…

This study tests whether combining procedures that block blood flow to liver tumors (TACE or HAIC) with targeted drugs and immunotherapy can help control advanced hepatocellular carcinoma that cannot be surgically removed. The trial enrolls adults aged 18–80 with large or vein-in…

This study tests a new way to give chemotherapy for gastrointestinal cancers like colorectal and stomach cancer. Doctors will adjust the dose of one chemo drug (5-FU) based on how well each patient tolerates it, aiming to give higher doses to those who can handle it without sever…

This study tests a new drug called YL201 in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two parts: first, finding a safe dose, then testing that dose in more patients with specific cancer types. YL201 is given by IV every t…

This early-phase study tests a new drug called BG-C137, which delivers chemotherapy directly to cancer cells that have a specific marker (FGFR2b). The goal is to see if it is safe and can shrink tumors in people with advanced solid tumors who have run out of standard options. Abo…

This early-phase study tests a new drug called BG-C0979, alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…

This study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…

This global Phase 3 trial is testing whether adding the experimental immunotherapy rilvegostomig to standard chemotherapy helps people with advanced biliary tract cancer live longer, compared to adding the approved drug durvalumab. About 1,100 participants with inoperable or meta…

This early-stage study tests a new drug called AO-252 in people with advanced solid tumors, including those that have spread to the brain. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or stop them from growing. About 86 adults whos…

This early-stage study tests a new drug called CBA-1205 in people with advanced solid tumors (like liver cancer or melanoma) that have not responded to other treatments. The main goal is to check the drug's safety and find the best dose. About 66 participants will receive the dru…

This study tests whether combining two drugs, YL201 and ivonescimab, can safely shrink tumors in people with advanced solid cancers, including lung cancer. About 260 adults whose cancer has not responded to other treatments will receive the combination. The goal is to find the be…

This phase 3 trial is testing whether adding a chemotherapy pump that delivers drugs directly to the liver (hepatic arterial infusion, or HAI) can help people with colorectal cancer that has spread to the liver and cannot be removed by surgery. About 408 participants will receive…

This study looks at whether adding lidocaine to standard sedation during radiofrequency ablation for liver cancer can reduce inflammation and lower the chance of the cancer returning. The researchers focus on a process called NETosis, which is linked to tumor growth and spread. O…

This study tests a combination of two drugs (apatinib and adebrelimab) plus chemotherapy (GEMOX) as a first treatment for people with advanced intrahepatic cholangiocarcinoma, a type of bile duct cancer that cannot be removed by surgery. The goal is to see if this mix shrinks tum…

This early-phase study is testing an experimental drug called 177Lu-IM-3050 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. About 105 participants will receive the drug to s…

This early-phase trial is testing a new drug called H1710 in 36 adults with advanced solid tumors who have no standard treatment options left. The main goal is to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also watch for any …

This phase 2 trial is testing a drug called datopotamab deruxtecan (Dato-DXd), alone or with other cancer medicines, in people with advanced or metastatic solid tumours. The study includes seven cancer types and aims to see if the drug shrinks tumours and how safe it is. Around 4…

This early-stage study tests a new drug called ALN-BCAT, given alone or with the immunotherapy Keytruda, in people with advanced or metastatic liver cancer that has a specific genetic mutation (WNT pathway). The trial aims to find safe doses and see if the drugs shrink tumors. Ab…

This phase 1 trial tests whether specially designed viruses (VSV-based oncolytic viruses) can safely treat advanced solid tumors that have not responded to standard treatments. The viruses are injected into the body to infect and destroy cancer cells. The study focuses on safety …

This study tests a new drug called AZD8205, alone or with another drug (rilvegostomig), in people with advanced solid tumors like breast, ovarian, and lung cancers. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 460 adults whose c…

This study has two parts. Part A tests whether cancer patients who stopped a type of immunotherapy (checkpoint inhibitors) due to side effects can safely restart treatment with durvalumab, given alongside the steroid prednisone to reduce the risk of side effects returning. Part B…

This Phase 2 trial is testing two experimental drugs (SSGJ-705 and SSGJ-612) with or without chemotherapy in 150 adults with advanced HER2-positive solid tumors, including colorectal, bladder, breast, bile duct, and stomach cancers. The goal is to see if the combination can shrin…

This early-stage trial is testing an experimental drug called MK-0472, alone or combined with the immunotherapy Keytruda or another experimental drug MK-1084, in people with advanced or metastatic solid tumors. The main goals are to check safety, find the right dose, and see how …

This large Phase 3 trial is testing whether a new drug called rilvegostomig, combined with bevacizumab and with or without tremelimumab, can help people with advanced liver cancer live longer. About 1,220 participants who cannot have surgery or other local treatments will be rand…

This phase 1 trial tests a new therapy called MSK-TCR5 for people with advanced solid tumors that have a specific genetic change (RAS G12D mutation) and a certain immune type (HLA-A*11:01). The therapy uses a patient's own T-cells, modified in a lab to better recognize and attack…

This early-phase trial is testing a new experimental drug called BNT3212, alone or with another drug (pumitamig), in 375 adults with advanced solid tumors who have no other treatment options. The main goals are to check safety, find the right dose, and get an early look at whethe…

This early-phase study is testing a new drug called OVV-01 in 18 people with advanced solid tumors that have not responded to standard treatments. The drug is given either through a vein or directly into a tumor. The main goal is to check safety and find the right dose, while als…

This study tests a new drug called AZD4360 in adults with advanced solid tumours that have a specific marker (CLDN18.2). The drug is an antibody-drug conjugate designed to deliver a toxic payload directly to cancer cells. The trial aims to find the safest dose and see if it shrin…

This early-stage trial is testing a new biologic drug, GEN1106, in about 103 people with advanced solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then refining it; finally, checking how well the drug shrinks tumors. All participants …

This study tests a new drug called IMP1734 in people with advanced solid tumors (breast, ovarian, or prostate cancer) that have not responded to prior treatments. The main goals are to check safety, find the right dose, and see if it shrinks tumors. About 156 participants will ta…

This study tests a new biologic drug, CM518D1, in people with advanced solid tumors that have not responded to standard treatments. The trial has two phases: first, to find the safest dose and check for side effects, and second, to see if the drug can shrink tumors. About 434 par…

This early-stage trial is testing whether giving durvalumab as a shot under the skin works as well as the standard IV infusion. About 40 adults with various solid tumours will receive the injection, and researchers will measure drug levels in the blood and watch for side effects.…

This early-stage study tests a new drug called STP938 in 70 adults with advanced solid tumors that cannot be cured by current treatments. The main goal is to check safety and find the right dose. The study also looks at how the drug moves through the body and includes a special g…

This study tests a new drug called HH-009 in people with advanced liver cancer that has worsened after other treatments. About 30 participants will receive one of two doses to see if it can slow or stop cancer growth. The goal is to find out if the drug is safe and effective.

This early-stage study tests a new drug called BAL0891, given alone or with chemotherapy or immunotherapy, in people with advanced solid tumors or acute myeloid leukemia (AML) that has come back or not responded to treatment. The main goals are to find a safe dose and check for s…

This early-phase study tests a new combination treatment for people with advanced pancreatic cancer that has spread or cannot be removed by surgery. The treatment uses specially engineered immune cells (NK cells) from donated cord blood, given through a belly infusion and a vein,…

This early-stage trial is testing an experimental drug called MBS8(1V270), given alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 1…

This early-phase trial tests an experimental drug called YH32367 in people with HER2-positive solid tumors that have spread or cannot be removed by surgery. The study has two parts: first, finding a safe dose, then testing that dose in specific cancer types like biliary tract can…

This study tests an experimental drug called YH32364 in adults with advanced solid tumors that have high levels of EGFR and have not responded to previous treatments. The trial has two parts: first, finding a safe dose in about 30 people, then testing that dose in 50 people with …

This study tests whether adding the drug lenalidomide to ongoing targeted therapy and immunotherapy can help people with advanced liver cancer whose disease has worsened after multiple prior treatments. About 32 participants will receive the combination and be monitored for tumor…

This study looks at the long-term safety and benefits of the drug pelabresib in people with blood cancers, solid tumors, or advanced cancers. It includes up to 50 adults who were in earlier pelabresib studies and are still benefiting from the drug. Some participants who received …

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can help control advanced solid tumors that have spread. About 115 adults whose cancer has worsened after at least one prior treatment will receive the combination. The main goal is to chec…

This study tests whether adding an experimental drug (D07001) to standard chemotherapy (capecitabine) helps people with advanced bile duct cancer live longer. About 195 adults whose cancer has not responded to earlier treatments will receive either D07001 or a placebo, plus capec…

This study tests a new way to give the drug rilvegostomig as a shot under the skin instead of through an IV. It is for adults with advanced solid tumors who have already tried standard treatments. The goal is to find a dose that works as well as the IV version and to check for si…

This study tests a new therapy called EB-HC01, which uses specially engineered natural killer (NK) immune cells to attack cancer cells that have two specific markers (HER2 and CEACAM5). The trial enrolls adults with advanced bile duct or gallbladder cancers that have worsened aft…

This early-stage trial tests a new drug called AN8025 in about 91 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Participants receive the drug in 3-week cycles and are closely moni…

This early-stage study is testing a new drug called MG2512 in about 116 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also w…

This study looks at whether getting standard immunotherapy in the morning (before 11 am) or afternoon (after 12 pm) changes how well it fights advanced or metastatic solid tumors. Researchers think the body's internal clock (circadian rhythm) might affect immune activity. About 1…

This study tests whether adding an immune-boosting drug (PDS01ADC) to standard chemotherapy delivered directly to the liver can help people with colorectal, bile duct, or adrenal cancer that has spread to the liver. About 70 adults will receive the drug combination along with a s…

This phase 2 trial tests a new radiation technique called SBRT-LATTICE-PATHY for people with large tumors (at least 7 cm or 340 cm³) that cannot be treated with standard methods. The approach delivers a high dose of radiation only to low-oxygen areas inside the tumor, aiming to i…

This early-phase study tests a new drug called CT-95 in people with advanced cancers that have a protein called mesothelin on their cells. The main goals are to find a safe dose and see if the drug can shrink tumors. About 70 adults with ovarian, lung, pancreatic, or other mesoth…

This study is testing a new robotic system that uses just one small incision to perform surgeries on the liver, pancreas, stomach, and esophagus. The goal is to see if this single-port approach is safe and works well for these complex operations. The study will enroll 35 adults w…

This study tests whether adding immunotherapy (adebrelimab) to different chemotherapy or targeted therapy regimens can help prevent cancer recurrence in people with intrahepatic cholangiocarcinoma who have a high risk of the cancer coming back after surgery. About 90 participants…

This study tests a new treatment using a patient's own immune cells, called CAR T cells, that are specially designed to target and kill solid tumor cells while leaving healthy cells unharmed. It is for adults with certain advanced cancers, including lung, colon, pancreatic, ovari…

This study tests whether a new drug combination (trastuzumab deruxtecan plus rilvegostomig) works better than standard chemotherapy for people with advanced bile duct cancer that has a specific protein called HER2. About 620 adults with untreated, advanced HER2-positive bile duct…

This early-stage trial is testing an experimental oral drug called EXS74539 (REC-4539) in about 40 people with various solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to check the drug's safety, find the right dose, and see how the body proce…

This study tests a new drug called BL-B01D1, alone or with other cancer drugs, in 74 people with advanced liver cancer that has spread. The goal is to see if these combinations can shrink tumors and how safe they are. Participants will receive the drugs through an IV or as pills …

This study tests a new drug called INV-8989 in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The trial has two phases: the first finds the safest dose, and the second checks how well the drug shrinks tumors. About 178 adults with cancers …

This phase 2 trial tests whether adding lenvatinib to the STRIDE regimen (durvalumab plus tremelimumab) works better than STRIDE alone for people with advanced liver cancer that cannot be surgically removed. About 140 adults who have not had prior systemic therapy will be enrolle…

This early-phase trial is testing a combination of three treatments for people with advanced biliary tract cancer that cannot be surgically removed. The approach delivers chemotherapy directly to the liver, along with an immunotherapy drug and a targeted therapy pill. The study a…

This early-stage trial tests a new drug called KO-2806, alone or with other cancer drugs, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for early signs of tumor shrinkage. About 300 participants wi…

This early-stage study tests a new drug called ADCX-020 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody drug conjugate designed to deliver cancer-killing agents directly to tumor cells. The study will first find th…

This study tests a new treatment made from specially engineered immune cells (T cells) donated by healthy people. The cells are designed to better recognize and kill cancer cells while lasting longer in the body. The trial includes 24 adults with blood cancers or solid tumors tha…

This study tests a new drug called IDE196 in people with certain cancers that have specific genetic mutations (GNAQ/11 or PRKC fusions). The cancers include metastatic uveal melanoma, cutaneous melanoma, and colorectal cancer. The trial has two phases: first to find safe doses, t…

This study tests a new treatment called ECT204 for adults with advanced liver cancer that has not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The trial will enroll 60 pe…

This early-stage study tests a new type of cancer vaccine made from irradiated tumor and nearby cells. It aims to see if the vaccine is safe and can help the immune system fight advanced solid tumors like osteosarcoma, pancreatic cancer, and others. About 54 people will take part…

This early-phase trial is testing a new drug called enzelkitug, alone or with standard immunotherapies, in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. A…

This early-stage study tests a chemotherapy drug (JNJ-1761981) that is injected directly into tumors in people with solid cancers that have not responded to standard treatments. The goal is to find a safe and effective dose, and to see if adding an immunotherapy (cetrelimab) help…

This study tests a new drug called IAH0968, given alone or with chemotherapy (CAPEOX), in people with advanced HER2-positive stomach cancer or other solid tumors. The goal is to see if the combination is safe and helps slow cancer growth better than standard treatment. About 574 …

This study tests a new drug called STX-478 in people with advanced solid tumors that have a specific genetic change (PI3Kα mutation). The trial has two phases: first, it tests STX-478 alone to find safe doses; then, it combines STX-478 with other cancer drugs like fulvestrant or …

This study tests a new cancer drug, repotrectinib, combined with standard chemotherapy in children and young adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if the combination can shrink tumors. Researchers will also study how the b…

This early-phase study tests a new radioactive drug, LY4337713, in people with advanced cancers that have high levels of a protein called FAP. The cancers include certain types of ovarian, breast, pancreatic, colorectal, esophageal, stomach, and bile duct cancers. The study aims …

This study tests a new drug called PF-08634404, given alone or with another drug (ipilimumab), in adults with advanced liver cancer that cannot be surgically removed. The goal is to check safety, side effects, and whether the drug shrinks tumors. About 138 participants will recei…

This phase 2 trial is testing whether an artificial intelligence system can find the best doses of three drugs (irinotecan, sonidegib, and sorafenib) for people with advanced liver cancer. The study will enroll 12 adults whose cancer has not responded to other treatments. The goa…

This study tests a culturally tailored support program for Black patients with early-stage liver cancer. The program includes education, help with social needs, and easier access to cancer specialists. Forty participants will be randomly assigned to the program or usual care and …

This study tests a new drug called OSE-279 that helps the immune system fight cancer. It is for people with advanced solid tumors or lymphomas that have not responded to other treatments. The trial has three parts: finding the right dose, checking safety, and measuring how well t…

This study is testing whether giving lower, less frequent doses of the cancer drug atezolizumab can still keep enough drug in the blood to fight cancer. About 30 adults with certain advanced cancers (like lung cancer or melanoma) will start with standard doses, then switch to a l…

This program provides the experimental drug ulixertinib to people with advanced solid tumors that have certain gene mutations (MAPK pathway). It is for patients who have not responded well to or have run out of standard treatments. The goal is to control the disease and possibly …

This study compares a precise radiation technique called SABR against standard treatments (like heat probes or chemo injections) for early-stage liver cancer. About 218 adults with a single tumor up to 8 cm will be randomly assigned to SABR or standard care. The main goal is to s…

This early-phase trial is testing an experimental oral drug called ABBV-CLS-484, either alone or combined with other cancer treatments, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study aims to find safe and tolerable doses and to se…

This study tests a drug called ivosidenib in people with a specific type of bile duct cancer (IDH1-mutated) that has been surgically removed. After standard chemotherapy, participants take ivosidenib daily to see if it helps keep the cancer from returning. The trial involves 40 a…

This early-phase study tests a virus (JNJ-87704916) that is injected directly into tumors to kill cancer cells. It is being tested alone and with another drug (cetrelimab) in people with advanced solid tumors who have run out of standard treatments. The main goals are to check sa…

This early-stage trial tests an experimental drug called TEV-56278, alone or with the immunotherapy pembrolizumab, in 240 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug…

This early-phase study tests a new drug called BG-C9074, designed to target and kill cancer cells in people with advanced solid tumors that have not responded to standard treatments. The study will first find the safest dose, then test it alone or with other cancer drugs. About 3…

This study tests whether adding tivozanib (a drug that targets blood vessel growth) to atezolizumab (an immunotherapy) can help the immune system attack cancers that normally resist immunotherapy. The trial includes people with several cancer types like bile duct, pancreatic, pro…

This early-stage trial tests an experimental drug called CTX-10726 in about 70 people with advanced gastroesophageal, liver, endometrial, or kidney cancers that have stopped responding to standard treatments. The main goal is to check safety and find the right dose. Participants …

This Phase 2 trial tests an oral drug called BAY 2927088 (sevabertinib) in about 111 adults with advanced solid tumors that have HER2 gene mutations. The drug aims to block the abnormal HER2 protein and stop cancer growth. Participants take a 20 mg tablet daily in 3-week cycles u…

This early-phase study is testing a new oral drug called BG-75202, alone or with other medications, in people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and …

This early-stage study is testing a new drug called BGB-B2033, alone or with other drugs, in people with advanced liver, stomach, or lung cancers. The goal is to see if it is safe and how well it works. About 392 participants will take part.

This early-phase study tests a new drug called BBO-11818 in people with advanced cancers that have a KRAS mutation, including lung, pancreatic, and colorectal cancers. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink tumors. Abou…

This study tests a new drug called AZD5335, alone or with other cancer medicines, in people with advanced solid tumors like ovarian, lung, and endometrial cancers. The goal is to see if the drug is safe, tolerable, and shows signs of shrinking tumors. About 506 participants will …

This early-stage trial is testing an experimental drug called HS-20108 in 502 people with advanced solid tumors that have spread or cannot be removed. The main goal is to find a safe dose and check for side effects. Researchers will also look for any signs that the drug might shr…

This early-phase study is testing a new drug called BGB-26808, either alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 217 partici…

This study is collecting information on how well the HistoSonics Edison System, which uses sound waves (histotripsy) to destroy liver tumors, works in everyday medical practice. Up to 5,000 adults with liver tumors will be followed for up to 5 years after treatment. The main goal…

This early-stage trial tests a new drug called SIM0613 in about 294 adults with advanced solid tumors that have worsened after standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. The main goals are safety and…

This early-stage trial is testing a new antibody called GEN1079 in people with certain advanced solid tumors. The study has three parts: first, finding a safe dose; then refining the dose; and finally, checking if the drug shrinks tumors. About 121 participants will receive the a…

This study tests whether a fecal microbiota transplant (FMT) can help liver cancer patients who stopped responding to standard drugs. Fifteen adults with advanced liver cancer will receive FMT along with atezolizumab and bevacizumab to see if the combination can restore tumor con…

This study tests a new drug called UI-102, which is a tiny nanoparticle designed to activate the immune system to fight cancer. It is for people with advanced solid tumors that have not responded to standard treatments. The trial will enroll 140 participants to first find the saf…

This early-phase trial is testing a new drug called IACS-6274, either alone or combined with other cancer drugs, in 54 adults with advanced solid tumors (such as melanoma, ovarian, or head and neck cancers). The main goal is to find the safest dose and understand side effects. Th…

This early-phase trial tests an experimental oral drug called ST-01156 in adults with advanced solid tumors that have spread or cannot be removed by surgery. The drug works by breaking down a protein inside cancer cells. The main goals are to find a safe dose and check for side e…

This study tests a new drug, MP0317, combined with standard chemotherapy and immunotherapy for people with advanced bile duct cancer that cannot be removed by surgery. The goal is to see if this combination helps keep the cancer from growing for at least 12 months. About 75 adult…

This early-phase study is testing a new biologic drug called JLM019 in adults with advanced solid tumors or lymphomas that have come back or not responded to treatment. The drug is given as a weekly intravenous infusion, and the main goals are to check its safety, find the right …

This study tests an experimental drug called RMC-9805, taken as a pill, in adults with advanced solid tumors (such as lung, colorectal, or pancreatic cancer) that have a specific mutation in the KRAS gene called G12D. The drug is given alone or in combination with another oral dr…

This study is for children whose solid tumors have returned or not responded to standard therapy. It combines an immunotherapy drug (atezolizumab) with three chemotherapy drugs to see if the mix is safe and can shrink tumors. About 23 children will take part, and the main goals a…

This study is testing a new experimental drug called BG-75098, given alone or with other medicines, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tum…

This early-phase study tests a new drug called RC220 given with the chemotherapy doxorubicin in adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find a safe dose and see if RC220 can protect the heart from doxorubicin's sid…

This early-phase trial tests a new biologic drug called SBO-154 in 177 people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrink…

This early-stage trial tests a new drug called AU409 in 36 people with advanced liver cancers or solid tumors that have spread to the liver. The main goals are to find the safest dose and check for side effects. Researchers will also look for signs that the drug might shrink tumo…

This early-phase study tests a new cell therapy for people with advanced biliary tract cancer (bile duct or gallbladder cancer) that has not responded to standard treatments. The therapy uses the patient's own immune T cells, enhanced with a protein called CD160 to better target …

This study tests an experimental drug called INV-6452 in adults with advanced breast cancer (HR+/HER2-) or other solid tumors that have stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 201 participants wil…

This study tests a new drug called ifinatamab deruxtecan in people with advanced solid tumors that have not been cured by other treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 250 participants will take part, and those who benefit may …

This early-phase study tests a new drug called CT3001 in people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose of CT3001 alone, then testing it combined wit…

This study tests an experimental drug, REGN7508, to see if it works better than the standard blood thinner apixaban for treating and preventing blood clots in people with cancer. The trial will include about 1,600 participants with or without cancer who have deep vein thrombosis …

The TAPUR study is testing a wide range of targeted cancer drugs in people with advanced solid tumors, lymphoma, or multiple myeloma whose tumors have specific genetic changes. The goal is to see if matching drugs to these genetic variants can shrink tumors or stop them from grow…

This early-phase study tests a new drug called BG-T187, a special antibody that targets two proteins (EGFR and MET) on cancer cells. It is given alone or with other drugs to people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safet…

This early-phase study tests a new experimental drug (BI 3819026) alone and with another drug (ezabenlimab) in adults with advanced solid cancers that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. About 60 particip…

This early-stage trial tests the safety of a new drug called ERX-315 in 36 adults with advanced solid tumors (like breast, ovarian, or pancreatic cancer) that have stopped responding to standard treatments. Participants receive the drug intravenously twice a week at increasing do…

This early-phase trial is testing a new drug, FOG-001, in about 595 people with advanced or metastatic solid tumors, including colorectal, prostate, and liver cancers. The drug is given alone or with other cancer treatments to see if it is safe and shrinks tumors. The study is cu…

This study looks at how the cancer drug ASTX727 (decitabine and cedazuridine) works in people with moderate or severe liver problems. About 27 adults with certain blood cancers or solid tumors will take the drug for up to 8 weeks. The goal is to understand how the liver affects t…

This study is testing a combination of three treatments—radioactive beads (SIRT-Y90), an immunotherapy drug (atezolizumab), and a drug that cuts off tumor blood supply (bevacizumab)—for people with advanced liver cancer that cannot be surgically removed. Researchers will track ho…

This early-stage study looks at how the body handles the cancer drug ASTX727 (decitabine and cedazuridine) in people with severe kidney problems compared to those with normal kidneys. It includes 18 adults with acute myeloid leukemia, myelodysplastic syndromes, or solid tumors. T…

This early-stage trial tests whether adding a chemotherapy drug (5-Azacitidine) to standard immunotherapy can help patients whose solid tumors have stopped responding to PD-1/PD-L1 inhibitors. About 35 adults with advanced or metastatic cancers will receive the combination to fin…

This early-phase study tests whether spending time in a cool room (around 18°C for 12 hours a day) can make standard immunotherapy drugs work better for people with solid tumors. Twenty-four adults with various solid cancers will receive cold exposure alongside their usual PD-1/P…

This early-phase study tests a new drug called GS-0201, given alone or with another cancer drug (sacituzumab govitecan), in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the best dose, and see how the body …

This early-stage trial tests a new drug called HLX316 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to help the immune system attack cancer cells. The study will check for safety, side effects, and whether the drug can s…

This study tests a combination of three drugs—chemotherapy infused directly into the liver, a targeted pill, and an immunotherapy—in 38 people with advanced liver cancer that has spread into the main portal vein. The goal is to shrink the tumor enough so that surgeons can remove …

This trial tests a new drug called TUB-030 in adults with advanced solid tumors, including head and neck, lung, and breast cancers. The goal is to find the safest and most effective dose. Participants receive the drug every three weeks and are monitored for side effects and tumor…

This early-stage trial tests a new drug called EVM14, given alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have spread or come back. The main goals are to check safety, find the right dose, and see if the drug helps control the cancer. A…

This study tests a new approach for people with a certain type of bile duct cancer that cannot be removed by surgery. Participants first receive chemotherapy and radiation, then a liver transplant. The goal is to see if this combination helps patients live longer and stay cancer-…

This study tests two surgical techniques for bile duct cancer that has spread to nearby lymph nodes. One method removes the bile duct completely to take out all affected lymph nodes, while the other leaves the bile duct in place but may leave some lymph tissue behind. The goal is…

This phase 2 trial is testing whether adding a procedure called radiofrequency ablation (bRFA) to standard chemotherapy and immunotherapy is safe for people with bile duct cancer that cannot be removed by surgery. About 36 participants will be randomly assigned to receive either …

This study is for adults with advanced liver cancer (hepatocellular carcinoma) that is hard to treat. It compares two standard drug regimens — immunotherapy (atezolizumab + bevacizumab) or targeted pills (lenvatinib or cabozantinib) — given after a liver-directed radiation treatm…

This study tests an experimental drug called LBL-024 combined with standard chemotherapy (cisplatin, gemcitabine) and bevacizumab in 140 people with advanced solid tumors. The goal is to see if the combination can shrink tumors and control the disease. Participants must be 18–75,…

This early-phase trial is testing a new drug called BG-C0902 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to attach to two proteins (EGFR and MET) often found on cancer cells and deliver a toxic payload directly to them…

This early-phase study tests a new drug called GSK5533524, alone or with other cancer treatments, in adults with advanced solid tumors that have stopped responding to standard therapies. The main goals are to find a safe dose and see if the drug can shrink tumors or slow cancer g…

This study tests whether using heat (radiofrequency ablation) to destroy cancer tissue inside the bile duct before placing a metal stent can keep the duct open longer than placing a stent alone. It involves 122 adults with inoperable bile duct cancer. The main goal is to see how …

This early-stage trial is testing a new drug that delivers a tiny amount of radiation directly to cancer cells. It is for people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to standard treatments. The study will check if the drug is…

This early-phase trial tests a new cell therapy called UCLH80-1 in 36 people with advanced solid tumors (colorectal, gastric, pancreatic, and bile duct cancers) that have not responded to standard treatments. The therapy uses specially engineered immune cells to target a protein …

This early-phase study tests a new drug called BGB-43395 in people with advanced HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. Researchers want to find the safest and most effective dose, either alone or combined wi…

This study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…

This study tests whether adding the experimental drug fostrox to the standard drug lenvatinib helps shrink tumors or slow cancer growth in people with advanced liver cancer. About 80 adults whose cancer worsened after initial immunotherapy will be randomly assigned to receive eit…

This study tests two new drug combinations (DB-1311 with BNT327 or DB-1305) in 450 adults with advanced or metastatic solid tumors that have not responded to other treatments. The main goals are to check safety and see if tumors shrink. Participants must be in fairly good health …

This Phase 3 trial tests whether a chemotherapy infusion directly into the liver (HAIC) plus immunotherapy drugs works better than the standard chemo-embolization procedure (TACE) plus the same immunotherapy for people with intermediate-stage liver cancer that has spread extensiv…

This study tests a type of internal radiation called high-dose-rate brachytherapy for people with liver tumors that cannot be surgically removed. The treatment uses a tiny radioactive source placed directly into the tumor to kill cancer cells while sparing nearby healthy tissue. …

This study tests a new drug, ALK201, for the first time in people with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 202 adults aged 18 to 75 will take part. The study is currently r…

This study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…

This study tests a new drug called DB-1324 in people with advanced or spreading stomach, bowel, or other gastrointestinal cancers that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumor…

This study tests a new drug called mocertatug rezetecan (Mo-Rez) combined with other cancer medicines for people with advanced solid tumors that have stopped responding to standard treatments. About 305 adults will join to see if the combination is safe, tolerable, and effective.…

This early-stage trial is testing a new drug called Risvutatug rezetecan (Ris-Rez) in people with advanced solid tumors that have spread or cannot be removed. The study will give Ris-Rez alone or combined with other cancer drugs like chemotherapy or immunotherapy. Researchers wan…

This phase 3 trial is testing whether giving a targeted therapy after initial standard chemotherapy can help people with advanced biliary cancer live longer without their disease getting worse. Participants must have a tumor with a specific genetic change and stable disease after…

This study tests a new drug called ivonescimab against standard chemotherapy (FOLFOX) for people with advanced bile duct cancer that has worsened after initial treatment. About 72 participants who were in the SAFIR-ABC10 trial will be randomly assigned to receive either ivonescim…

This study tests a new experimental drug called mavrostobart (PT199) in people with advanced solid tumors, specifically non-small cell lung cancer and pancreatic cancer. The drug is given alone or combined with other cancer treatments. The goal is to find the safest dose and see …

This study is testing a combination of four drugs—atezolizumab, sorafenib, bevacizumab, and cyclophosphamide—in children and young adults with solid tumors that have come back or not responded to standard treatment. The goal is to find safe doses and see if the combination can sh…

This early-stage study tests a new drug (177Lu-DOTA-SNA040) that delivers radiation directly to cancer cells with a specific marker (Claudin 18.2). It is for people with advanced stomach, pancreatic, or bile duct cancers that have worsened after standard treatment. The main goals…

This study is for children and young adults (ages 1 to 30) whose solid tumors have come back or not gone away with standard treatment. It tests two different drug pairs: one combines Onivyde with talazoparib, the other Onivyde with temozolomide. Both work by damaging cancer cell …

This early-stage trial is testing a new drug, QLS5212, in 100 people with advanced solid tumors that cannot be removed by surgery or have spread. The drug is an antibody-drug conjugate designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to find …

This early-stage trial is testing a new mRNA-based drug called MT-304, alone or with the immunotherapy nivolumab, in adults with advanced HER2-expressing solid tumors. The main goals are to check safety, find the right dose, and get a first look at whether it shrinks tumors. Abou…

This early-stage trial tests a new immunotherapy for children and young adults up to age 21 with solid tumors that have come back or not responded to standard treatment. The therapy uses the patient's own immune cells, which are modified in a lab to recognize and attack a protein…

This early-phase study is testing a new treatment called KXV01 for people with advanced solid tumors, including sarcomas, who have no other options. The therapy uses a patient's own immune cells, modified with a virus to recognize and attack their specific tumor. The main goal is…

This study tests a new drug called BOLD-100 combined with standard FOLFOX chemotherapy in people with advanced colorectal, pancreatic, stomach, or bile duct cancers that have spread or cannot be removed. The goal is to see if the combination is safe and helps control tumor growth…

This study tests a new drug called AU-007 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is designed to help the immune system fight cancer. About 159 participants will receive AU-007 alone or with other medicines to find the safes…

This study looks at whether adding focused radiation to spots where cancer is growing can help people with advanced liver cancer whose first immunotherapy treatment has partly stopped working. About 30 adults with limited new growth will receive radiation to those spots while con…

This study tests a new drug, SKB103, in people with advanced solid tumors who have run out of standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors or slow their growth. About 277 adults aged 18 to 75 will take part.

This early-phase trial tests AMT-676, a drug designed to seek out and destroy cancer cells that carry a protein called CDH17. It is given intravenously to 24 adults with advanced solid tumors (such as colorectal, gastric, or pancreatic cancer) that have not responded to prior tre…

This early-phase study tests CBX-12 in about 35 adults with advanced solid tumors that have spread and stopped responding to prior treatments. CBX-12 works by entering cancer cells and damaging their DNA, which can kill the cells. Researchers will measure how well the drug trigge…

This early-phase trial is testing whether combining two targeted drugs, pemigatinib and afatinib, is safe and can shrink tumors in people with advanced solid cancers that have specific FGTR gene changes. The study includes up to 70 participants whose cancers have spread or cannot…

This early study tests a new treatment for people with stage 4 solid tumors that have stopped responding to standard care. Patients receive an injection of iron-containing nanoparticles that travel to the tumor, then a machine creates a magnetic field to heat the particles and da…

This study is the first time the drug BNT3214 is being tested in people. It aims to find a safe and effective dose for adults with advanced solid tumors. The trial has three parts: first, finding the best dose; then, testing it in different cancer types. About 533 participants wi…

This program offers early access to a combination of two immunotherapy drugs, botensilimab and balstilimab, for people with serious or life-threatening cancers like colorectal, pancreatic, lung, liver, melanoma, sarcoma, ovarian, or prostate cancer. It is for patients who have tr…

This early-phase study tests a new drug called DS5361b, alone or with another drug (pembrolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…

This study tests whether adding all-trans retinoic acid to romiplostim N01 can better raise platelet counts in adults who have low platelets after finishing chemotherapy for gastrointestinal cancers. About 220 participants will receive either the combo or romiplostim alone for 12…

This study tests a new drug called AVZO-1418 in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if it shrinks tumors. About 480 adults will take part, receiving the drug alone or with other treatments.

This study tests a combination of two drugs, GNS561 and trametinib, in people with advanced bile duct cancer that has a specific genetic change (KRAS mutation) and has not responded to standard first-line therapy. The trial has two phases: first to find the safest dose, then to s…

This study tests a new drug called BNT329 in people with advanced solid tumors that have a specific marker (CA19-9). The main goals are to check safety and find the best dose. About 245 participants will take part. The drug works by targeting cancer cells and may help control tum…

This early-phase trial is testing whether combining a targeted radiation treatment (Y90 radioembolization) with two immunotherapy drugs (durvalumab and tremelimumab) is safe and shows promise for people with bile duct cancer that cannot be removed by surgery. The study will enrol…

This study tests a new treatment for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells (T-cells) that are genetically modified in a lab to recognize and attack a protein called PRAME found on cancer cel…

This early-phase trial tests a new drug called SXRN, made from DNA, in 28 people with advanced solid tumors who have run out of standard options. The main goals are to check safety and find the right dose, while also seeing if it helps with appetite and physical function. The stu…

This early-phase trial is testing a new treatment called Super CAR-T for people with advanced hepatocellular carcinoma, a type of liver cancer that has spread. The treatment involves taking a patient's own immune cells, modifying them to better recognize and attack cancer cells, …

This early-stage trial is testing a new drug called IBI3028 in people with advanced solid tumors that cannot be removed by surgery or have spread. The drug works by attaching to two proteins (EGFR and c-Met) found on some cancer cells and delivering two anti-cancer agents directl…

This study tests a mix of five oral drugs (hydroxychloroquine, metformin, sirolimus, dasatinib, and nelfinavir) in people with advanced solid tumors or prostate cancer that has come back. The goal is to find the safest dose and see if the combination can stop the cancer from grow…

This early-phase study tests a new drug called TAK-243 in adults with advanced solid tumors or lymphoma that has not responded to standard treatments. The main goal is to find the safest dose and check for side effects. TAK-243 works by blocking a protein that cancer cells need t…

This early-phase trial is testing a new drug called IUAb190708, an antibody designed to attack cancer cells by targeting a protein called PD-L1. The study involves 90 adults with advanced or recurrent solid tumors who have run out of standard treatment options. The main goal is t…

This study tests whether a sequence of treatments—chemotherapy infused into the liver, two drugs (durvalumab and bevacizumab), and targeted radiation—can shrink advanced liver cancer enough to allow surgery. About 30 adults with liver cancer that cannot currently be removed will …

This early-phase study is testing a new drug called PEEL-224 in 65 people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the drug can shrink tu…

This early-stage study tests a new drug called SIGX1094R in about 102 adults with advanced solid tumors who have no standard treatment left. The main goals are to check the drug's safety, find the right dose, and see how it affects tumors. Researchers will also look at how food c…

This study tests two drugs, sapanisertib and cabozantinib, together in people with advanced liver cancer that has a specific genetic change (β-catenin mutation). The goal is to find the safest dose and see if the combination can slow or stop tumor growth. About 92 participants wi…

This study is testing an experimental oral drug called RMC-6236 in adults with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have specific RAS mutations. The main goals are to find safe doses and understand side effects. About 754 participants will take…

This clinical trial is testing a new drug called VRT106 combined with two other drugs (camrelizumab and apatinib) in people with advanced liver cancer that has not responded to prior immunotherapy. The study will enroll 66 participants and aims to see if the combination is safe a…

This early-phase study tests an experimental drug called VAX014, which is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The study will first find a safe dose of VAX014 alone, then te…

This early-phase trial tests a new treatment made from specially engineered cord blood cells (TROP2-CAR-NK cells) in adults with advanced solid tumors that have not responded to standard therapies. The main goal is to find a safe dose and monitor side effects. Up to 54 participan…

This study tests a powerful combination of treatments for people with advanced liver cancer that cannot be surgically removed. The approach uses heat-based ablation to destroy the main tumor, followed by targeted therapy (lenvatinib), immunotherapy (tislelizumab), and a procedure…

This study compares two imaging methods—contrast-enhanced ultrasound and abbreviated MRI—to see which is better at detecting early-stage liver cancer (HCC) in people with suspicious but not yet cancerous liver nodules. Researchers will enroll 600 adults with cirrhosis and indeter…

This study aims to create a simple blood test to find liver cancer at an early, more treatable stage. Researchers will analyze genetic material in the blood of 600 adults, including those with liver cancer, chronic liver disease, and healthy volunteers. The goal is to improve ear…

This study tests a new radioactive tracer called 68Ga-GPC3 that targets a protein found on liver cancer cells. About 40 adults with suspected or confirmed hepatocellular carcinoma will receive both this new tracer and a standard tracer (18F-FDG) for PET/CT scans. Researchers will…

This study is testing whether a new blood test can screen for many types of cancer at once. Researchers will enroll 24,000 adults aged 45-75 who do not have cancer. Participants will be randomly assigned to one of two blood test groups or a control group. The goal is to see how w…

This study is testing whether adding a special PET scan (using F18-Piflufolastat) to standard imaging can better diagnose and stage liver cancer. Researchers will enroll 90 veterans with suspected or confirmed hepatocellular carcinoma. The goal is to see if the scan helps clarify…

This study tests whether a special type of CT scan (spectral CT) can better detect remaining liver cancer after a standard treatment called TACE. About 121 adults with liver cancer who have had TACE will get a spectral CT scan, and results will be compared to standard CT and to a…

This study is testing whether a blood test that looks for a marker called mSEPT9 can predict liver cancer in people with cirrhosis. Researchers will follow 400 patients for up to 5 years, taking blood samples every 6 months to see if changes in this marker signal cancer risk. The…

This study tests whether contrast-enhanced ultrasound (CEUS) can better detect if liver cancer (HCC) has been killed by radioembolization treatment. Standard CT or MRI scans often take months to show clear results, delaying further treatment. Researchers will enroll 30 patients a…

This study is testing a new ultrasound imaging method called Contrast Enhanced Super-Resolution (CESR) to see if it can better detect and tell apart cancerous and non-cancerous lesions in the breast, liver, and kidney. It involves 40 participants: 10 healthy volunteers to fine-tu…

This early-phase study tests a new radioactive tracer called FAP-2286 to see how well it can detect cancer that has spread in adults with solid tumors. About 191 participants will receive the tracer and then have a PET scan. The goal is to measure safety and how clearly the trace…

This study tests a special dye called Cytalux that makes cancer cells glow under near-infrared light. Surgeons use it during lung surgery to find and remove hard-to-see tumors in teens (ages 6-17) with bone cancer that has spread to the lungs. The goal is to see if the dye helps …

This study is testing a new type of PET scan that uses special radioactive tracers to find and map solid tumors in the body. The tracers target a protein called Trop2, which is often found on cancer cells. Researchers will enroll 400 people with various cancers (including bladder…

This study is testing whether proteins in the blood can help detect liver cancer at an early stage. Researchers will compare blood samples from 600 people—some with liver cancer and some healthy—to find protein patterns that signal the disease. The goal is to create a simple, non…

This study is testing a special MRI scan that uses a unique contrast agent to see how aggressive advanced solid tumors are and how they respond to treatment. About 65 people with advanced solid tumors will get the scan before and during their standard cancer therapy. The goal is …

This early-stage study tests a new imaging agent called 18F-4FN for PET scans to safely detect inflammation in the body. It involves 55 adults with cancer who are on immunotherapy or have suspected inflammation. The goal is to see if this agent can highlight areas of inflammation…

This study tests whether a new imaging agent called [18F]FAPI-74 can find certain cancers as well as or better than the standard PET tracer. About 320 adults with one of 11 cancer types (including pancreatic, liver, ovarian, and lung cancers) will receive both tracers and have th…

This study is testing a new blood test that looks for DNA from cancer cells. The goal is to see if an artificial intelligence program can accurately detect many different types of cancer at an early stage. The study will include 6,000 adults, some with cancer and some healthy vol…

This study tests a new endoscopic ultrasound method (EUS-SWQ) to measure liver stiffness and diagnose liver fibrosis (scarring) in people with chronic liver disease. Researchers will compare EUS-SWQ results with standard liver biopsy and FibroScan in 65 adults. The goal is to see…

This pilot study is testing a new radioactive tracer called 89Zr-TLX250, which targets a protein (CAIX) found on certain tumor cells. The goal is to see if PET-CT scans using this tracer can detect more tumor lesions in people with liver cancer, bile duct cancer, or neuroendocrin…

This study is testing a new blood test that looks for DNA and protein signals from cancer cells. The goal is to find multiple types of cancer early, before they cause symptoms. Researchers will compare blood samples from 20,000 people with and without cancer to see if the test wo…

This study is testing a new imaging agent called 18F-T2, which is designed to highlight tumors that produce a protein called CAIX. About 200 adults with various cancers (like kidney, lung, or breast cancer) will receive an injection of 18F-T2 and then undergo a PET/CT scan. The g…

This study tests if a faster MRI scan, combined with a blood test, can find liver cancer earlier than the standard ultrasound in people with cirrhosis. The goal is to catch cancer at an early, more treatable stage and reduce deaths from liver cancer. About 4,700 veterans with cir…

This trial tests whether a different way of closing the abdominal wall during liver tumor surgery can lower the chance of developing an incisional hernia. 140 patients will be randomly assigned to receive either the new 'short stitch' method or the traditional closure. Researcher…

This phase 3 trial tests an experimental drug called REGN7508 to prevent blood clots in people with solid tumors who are receiving cancer treatment. About 1,120 participants will receive either the drug or a placebo. The study measures how well the drug prevents clots and checks …

This study tests whether a special algorithm called PAGODA can reduce unplanned delays during FOLFOX chemotherapy for gastrointestinal cancers like colon, stomach, and esophageal cancer. About 420 participants will be randomly assigned to either standard care or the algorithm-gui…

This study tests whether cancer patients can complete a supervised exercise program from home using video calls. The program includes resistance training with dumbbells and aerobic exercise. Researchers want to see if this approach is practical and helps patients maintain functio…

This study adapts a program called CONVO for Spanish-speaking Latinx adults with solid tumors. In the program, nurses talk with patients about their personal values during routine cancer care. The goal is to make care more respectful and supportive. About 234 adults will take par…

This study tests a new augmented reality system called LUMENA that helps doctors guide needles during MRI scans of the liver. Twenty adults having a liver biopsy or tumor ablation will try the device. The goal is to see if it is safe and works well enough to use in most procedure…

This study tests whether eating only within an 8-hour window (time-restricted eating) can improve how well cancer treatments work and reduce side effects. It involves 100 Alaska Native and American Indian patients with breast or rectal cancer. Participants will follow the eating …

This study is testing whether a time-restricted eating plan (eating only during an 8-10 hour window each day) combined with a healthy plant-based diet is safe and doable for people with liver cancer, cirrhosis, or fatty liver disease. Fifty overweight or obese adults will either …

This study compares two ways to manage pain after open liver surgery: a newer erector spinae plane block (ESPB) and the standard thoracic epidural. Sixty adults having elective open liver resection will be randomly assigned to one method. The goal is to see if ESPB provides simil…

This study observes about 700 people with lung or liver cancer who are already receiving atezolizumab as a shot under the skin. Researchers want to see how satisfied patients are with this treatment and how it affects their quality of life. The study does not test a new drug but …

This Phase 3 trial tests whether the experimental drug paltusotine can reduce flushing and diarrhea in adults with carcinoid syndrome caused by neuroendocrine tumors. About 141 participants will receive either paltusotine or a placebo daily for 12 weeks. The study measures how mu…

This study compares two types of nerve blocks—coeliac plexus block and splanchnic nerve block—to see which one reduces pain better in adults with upper abdominal cancer. Forty-four participants will receive one of the procedures and be monitored for pain, opioid use, and quality …

This trial investigates whether an online, nurse-guided version of cognitive behavioral therapy (CBT) can reduce severe fatigue in people with advanced cancer who are receiving palliative systemic treatment. Participants complete a 12-week online CBT program with support from the…

This study compares a newer, less invasive endoscopic procedure to standard surgery for treating gastric outlet obstruction, a blockage that prevents food from leaving the stomach. The trial will enroll 32 adults with advanced cancers causing this blockage. The main goal is to se…

This early-stage trial tests a new drug called GB18 in 18-36 cancer patients who are losing weight and appetite due to their illness (cachexia). The drug is given as a shot under the skin. The main goal is to check safety, but researchers will also see if it helps patients gain w…

This study tests special gloves and boots that gently squeeze the hands and feet during chemotherapy. The pressure may reduce how much chemo reaches the nerves, possibly preventing pain and numbness. About 142 adults with cancer will try the devices to see if they help avoid nerv…

This phase 3 trial tests whether a precise, high-dose radiation technique (SBRT) provides better pain relief than standard radiation for cancer patients with painful bone metastases not in the spine. About 230 adults with solid tumors and moderate to severe pain will be randomly …

This study compares giving the cancer drug nivolumab (Opdivo) as a shot at home versus in a clinic for people with various advanced cancers. The goal is to see if home treatment improves patients' overall care experience and quality of life. About 50 adults will receive the drug …

This study tests whether a high-protein nutrition plan combined with resistance exercises, started weeks before surgery and continued for 24 weeks after, can help older adults with cancer preserve their physical function. The trial enrolls Veterans aged 55 and older with certain …

This study looks at whether a culturally tailored Latin dance program can help Hispanic cancer survivors sleep better. Researchers will enroll 40 adults who have finished their main cancer treatment but still have trouble sleeping. Participants will either take dance classes or c…

This study compares giving cancer treatment at home versus in a clinic for 27 adults with various cancers in the Florida Panhandle. The goal is to see if home treatment is preferred and improves satisfaction, while also checking safety. Participants will receive their usual cance…

This pilot study tests whether brodalumab, a drug used for autoimmune conditions like psoriasis, can safely reduce immune-related side effects caused by cancer immunotherapy. About 11 adults with advanced solid tumors who developed these side effects will receive brodalumab injec…

This study tests whether people with liver cancer can be safely treated as outpatients instead of staying in the hospital after a procedure that delivers treatment directly to the liver's blood supply. About 206 patients will be randomly assigned to either outpatient or standard …

This study aims to collect blood, urine, tumor samples, and health data from up to 1,000 people with malignant mesothelioma or other cancers that express a protein called mesothelin. Participants will be followed over time to track the course of their disease. The goal is to buil…

This study tests a program where patients with liver cancer meet with a navigator who helps them connect to medical and community resources. The goal is to understand patient needs and improve access to care and research participation. Adults with hepatocellular carcinoma or othe…

This study collects extra blood, urine, and tumor samples from children and adults with certain cancers to build a large tissue repository. Researchers will analyze these samples to learn more about the genetic and molecular makeup of these tumors. The goal is to support future s…

This study looks at 100 people who have had a Whipple procedure (pancreaticoduodenectomy) for cancers of the pancreas or nearby areas. The goal is to find factors before, during, and after surgery that raise the risk of a pancreatic fistula—a leak of digestive fluid that can caus…

This study looks at a standardized method for giving high-dose radiation a second time to people with solid tumors that have come back. It uses advanced imaging to better calculate radiation doses to sensitive organs like the spinal cord and gut. The goal is to track how often se…

This study follows 6,000 adults with solid tumors who are receiving immune checkpoint inhibitors as part of their routine cancer care. Researchers are tracking how long patients live and how long their disease stays under control. The goal is to learn how well these drugs work in…

This study at the National Institutes of Health is looking at 1,000 adults with known or suspected hormone gland (endocrine) disorders. The goal is to better understand these conditions and help train doctors. Participants may receive tests, treatments, or surgery as part of thei…

This study explores whether a blood test that detects circulating tumor DNA (ctDNA) can help doctors personalize treatment for people with five types of advanced cancer: non-small cell lung cancer, gastrointestinal stromal tumors, colorectal cancer, biliary tract cancer, and ovar…

This study is building a huge registry of information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. Researchers will use this resource to study what causes cancer and how to better prevent, detect, and treat it. The re…

This study is collecting live tumor samples from 2,000 cancer patients undergoing standard biopsies. Researchers will analyze these samples to understand how tumors respond to immunotherapy drugs outside the body. The goal is to develop a method to predict which patients will res…

This study investigates why some liver cancers respond to immunotherapy (atezolizumab plus bevacizumab) after surgery while others do not. Researchers will collect detailed molecular data from tumors and blood samples of 30 patients to find biomarkers that predict response, resis…

This study is observing 200 adults with advanced liver cancer who are starting a new treatment with two drugs, tremelimumab and durvalumab. Researchers want to see how long it takes for liver problems to get worse, how patients feel, and how safe the treatment is in everyday medi…

This study enrolls up to 15,000 children with known or suspected endocrine or metabolic disorders, along with their family members. Researchers will collect medical records, blood, saliva, and other samples to identify genetic changes linked to these conditions. The goal is to be…

This study looks at how the drug mirdametinib is absorbed and removed from the body in people with moderate or severe liver problems compared to those with normal liver function. It involves 32 adults and is for research only, not to treat any condition. The goal is to understand…

This study enrolls 1,000 adults with advanced solid tumors that have progressed after standard treatment. Researchers will use genetic tests to match patients to specific drugs, like Alectinib or Atezolizumab, based on their tumor's gene changes. The goal is to see if this person…

This study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …

This study is testing how to safely perform skin allergy tests in people receiving biotherapies for cancers and blood disorders. Researchers will find the highest concentration of each biotherapy that does not cause a skin reaction in 9 out of 10 patients. The goal is to establis…

This study tracks 770 adults with advanced solid cancers (like lung, head and neck, melanoma, or bladder cancer) who are receiving immunotherapy. Researchers collect tumor and blood samples over time to find biological markers that predict how well the treatment works or causes s…

This study aims to safely collect health information like heart rate and activity levels from cancer patients using devices like smartphones and wearables. Researchers will use this data to learn more about how it relates to cancer diagnosis, treatment response, and risk factors.…

This study aims to collect medical data and biological samples (blood, urine, stool, and tissue) from up to 4,000 adults with known or suspected gastrointestinal diseases. Participants receive standard medical care at the NIH, and any extra samples or leftover tissue from procedu…

This early-stage study looks at how a new drug, INCB123667, behaves in the bodies of 16 adults with moderate or severe liver disease. Researchers will measure drug levels and watch for side effects. The goal is to gather safety information, not to treat the liver condition.

This study looks at tumor samples from 2,100 Chinese patients with lung, gynecologic, bile duct, or bladder cancers. Researchers will compare different HER2 testing methods to see how well they agree with each other. The goal is to improve the accuracy of HER2 testing, which help…

This study is building a prediction model to estimate the risk of heart injury after major liver surgery. Researchers will track 1800 patients undergoing hepatobiliary surgery and analyze factors like surgical technique and routine blood tests. The goal is to create a tool that h…

This study looks at 100 people with advanced solid tumors whose cancer stopped responding to immunotherapy. Researchers will take a fresh tumor sample and blood tests to compare genetic and immune differences between those who never responded and those who initially improved but …

This study is testing whether a special PET scan (18F-FSPG) and a blood test for tumor DNA can help doctors better guide treatment for liver cancer. About 60 people with hepatocellular carcinoma will receive standard Y90 radioembolization therapy. The goal is to see if these test…

This study is collecting detailed genetic and health information from 500 people with various cancers, including breast, lung, and leukemia. The goal is to create a shared database that helps researchers develop more personalized treatments. Participants provide samples and data,…

This study is collecting blood, urine, and stool samples from 300 people with cirrhosis to build a biobank. Researchers will later use these samples to understand how factors like nutrition, physical activity, smoking, alcohol, and pollution influence the development of the most …

This study aims to build an AI model that uses medical images and tissue samples to predict which liver cancer patients will benefit from additional treatments after surgery. Researchers will analyze data from 11,000 patients to see if the AI's recommendations match real-world ou…

This early-stage study is testing how the drug BMS-986435 behaves in the body and whether it is safe for people with mild to moderate liver problems compared to those with healthy livers. 24 adults will receive a single dose, and researchers will measure drug levels and monitor f…

This study is looking at special markers in the blood (called biomarkers) to learn more about how to detect, diagnose, and track solid cancers. Researchers will collect blood samples from 6,000 adults with solid cancer and analyze them alongside standard tests. The goal is to see…

This study is collecting stool and blood samples from 120 advanced cancer patients receiving immunotherapy combinations. Researchers want to see if the types of bacteria in the gut and certain immune markers can predict which patients will develop serious side effects. The goal i…

This early-phase study looks at how a single dose of the drug inavolisib behaves in people with moderate or severe liver impairment compared to healthy volunteers. Researchers will measure drug levels in the blood and check for side effects. The goal is to understand if liver pro…

This study looks at how a single dose of the experimental drug BI 1291583 behaves in the blood of people with and without liver problems. The drug is being developed for bronchiectasis, a chronic lung disease. About 32 adults aged 18–80 will take part, divided into groups based o…

This study looks at how T cells (a type of immune cell) respond to liver cancer and cancers linked to Epstein-Barr virus (EBV) and human papillomavirus (HPV). About 105 participants will give blood and tissue samples once. Researchers will analyze these samples to identify cancer…

This study collects blood or apheresis samples from 24 people with solid tumors and healthy volunteers. Researchers will analyze immune cells to see how they respond to a neoantigen vaccine, which is designed to help the immune system recognize cancer. The goal is to learn how to…

This early-stage study tests whether people with advanced solid tumors can safely follow a diet low in methionine, an amino acid found in many proteins. Researchers will measure how well participants stick to the diet, check for side effects, and track changes in blood methionine…

This study is gathering information from 800 people with liver cancer to track their diagnosis, treatments, and long-term health. The goal is to create a detailed database that helps doctors see what works best in real-world care. Participants must be 18 or older and treated at T…

This early-phase study tests a new radioactive tracer called [89Zr]DFO-starPEG to see if it can make tumors show up better on PET scans. The goal is to learn how the tracer behaves in the body and whether it can help doctors see the "leakiness" of tumor blood vessels, which may g…

This study aims to learn how genes and the environment contribute to rare tumors and cancer risk in individuals and families. Researchers will collect medical histories, genetic samples, and health data from up to 500 participants of all ages. No treatment is given; the goal is t…

This study collects blood, urine, bone marrow, and tumor samples from people with hairy cell leukemia and other blood cancers, as well as from healthy volunteers. Researchers will use these samples to study the diseases and develop new treatments called immunotoxins, which use an…

This early-stage study is testing a single dose of the drug eloralintide in 36 people with different levels of liver function—from healthy to severely impaired. Researchers want to see how the body absorbs and processes the drug and whether it causes side effects. The goal is to …

The JADE study is a large registry that will follow 1,000 people with liver or bile duct cancer in Germany. Its goal is to collect information on how these cancers are actually treated in routine care, including treatments, outcomes, and patient quality of life. No experimental d…

This study follows 600 childhood cancer survivors aged 8-18 to understand why symptoms like fatigue, pain, and depression often occur together. Researchers will use questionnaires and stool samples to see if gut bacteria and their byproducts play a role. The goal is to find bette…

This study tests a new communication tool called 'Let's Get REAL' that helps children and teens (ages 8-17) and their families talk together about stem cell transplant or cellular therapy decisions. The goal is to see if the tool is easy to use and helpful for families. About 60 …

This study aims to collect and analyze tumor samples from 10,000 adults with advanced solid cancers (like breast, lung, or colon cancer) to create a province-wide gene database. The goal is to help doctors identify which targeted drugs or clinical trials might work best for each …

This study looks at how the cancer drug olutasidenib affects the way the body processes other medications. Researchers will give 16 adults with IDH1-mutated cancers a mix of test drugs before and during olutasidenib treatment to measure changes in drug levels. The goal is to ensu…

This study provides long-term follow-up for people who previously received gene therapy or other immunotherapy for cancers like prostate, liver, breast, colon, or lung cancer. Participants will have annual health check-ups or phone calls for up to 15 years to monitor for any long…

This study looks at whether measuring a substance called FMN in the fluid used to preserve donated livers can predict how well the liver will work after transplant. Researchers will collect samples from 850 liver transplant patients at multiple hospitals. The goal is to see if FM…

This study looks at ways to personalize treatment for people with liver cancer (hepatocellular carcinoma). Researchers want to find out which patients are likely to respond to immunotherapy by testing their tumor tissue and blood before treatment starts. The goal is to avoid givi…

This observational study collects tumor tissue and blood cells from 200 people with advanced solid tumors like colorectal, lung, and pancreatic cancers. The goal is to understand how often tumors lose a specific marker (HLA) and to store participants' own T cells for potential fu…

This study uses a special microscope called intravital microscopy to look at blood vessels inside solid tumors while patients are in surgery. Researchers want to see how these vessels work and how well they let blood and dye flow through. The goal is to learn whether tumor vessel…

This early-stage study looks at how the liver handles two experimental drugs, AZD9550 and AZD6234, in people with moderate to severe liver problems compared to healthy volunteers. About 28 adults will receive a single injection of one drug. The goal is to see if liver impairment …

This study collects blood and other biospecimens from adults with cancer to analyze immune-suppressing cells and genetic changes. Up to 1,750 participants will provide samples before and after chemotherapy. The goal is to better understand how cancer affects the immune system, bu…

This early-stage study by Pfizer looks at how different levels of liver function affect the processing of a new drug called PF-07328948. About 26 adults with and without liver impairment will take a single tablet and stay at the clinic for 6 days for monitoring and blood tests. T…

This study is testing whether genetic testing of tumors and blood can help doctors choose better treatments for people with rare cancers. About 400 adults with rare solid tumors or lymphomas will have their tumors genetically analyzed. A team of experts will review the results an…

This study aims to find tiny genetic markers (microRNAs) and blood chemicals that can tell doctors early whether a liver cancer patient will fully respond to heat-based tumor destruction. Researchers will analyze blood and tumor tissue samples from 150 adults with early-stage liv…

This study is for Black adults newly diagnosed with gastrointestinal cancer. It focuses on ensuring patients receive proper biomarker testing and evidence-based care, helping them find and join clinical trials if they choose, and providing easy-to-understand information about the…

This study is creating a large database of 2000 people whose cancer has spread to the liver. Researchers will collect information on patients' health, treatments, and outcomes to learn more about the disease and improve future care. No new treatments are being tested; the goal is…

This study creates miniature, lab-grown versions of liver cancer tumors from patient biopsies. Researchers will test how well different treatments work on these models and look at how gut health and the tumor's environment affect the disease. The goal is to better understand live…

This study is developing an AI system that tracks tumors and organs during radiation therapy without needing physical markers. Researchers will use existing patient data to train and test the AI. If it works, it could help doctors target radiation more accurately. The study invol…

This study looks at how radiation treatment for esophageal cancer affects the body's ability to respond to the pneumonia vaccine. Researchers will give the vaccine to 80 patients who have low white blood cell counts after chemoradiation. They want to see if the vaccine still work…

This study looks at images from 50 liver cancer patients who received a special dye (contrast agent) during a procedure before radiation therapy. Researchers want to see if a software program (KIM) can detect that dye in the images to better track the tumor during treatment. The …

This early-stage study is recruiting 44 adults aged 18 to 80, including both healthy people and those with liver problems. All participants will take a single tablet of the drug BI 3000202. Researchers will measure how the drug moves through the body and check for side effects ov…

This study analyzes the DNA of solid tumors from 5,500 cancer patients to find genetic changes that could be targeted by specific treatments. The goal is to use this molecular profile to match patients with appropriate clinical trials. Participants must have a confirmed solid tum…

This study is for people with advanced solid tumors who have run out of standard treatment options. Researchers will track how well off-label or non-standard therapies work when chosen based on the tumor's genetic profile. The goal is to create a standard way to measure responses…